Publications

Halford Biosketch

 

Patents

  • Davido, D. and W.P. Halford, Issued Aug 2014, “Herpes simplex virus mutant ICP0.” U.S. Patent Number 8,802,109. Mutations in the ICP0 protein of any alpha-herpesvirus will yield an interferon-hypersensitive viral mutant that is (1) avirulent and yet (2) elicits protective immunity against superinfection with wild-type virus. (Read Patent)
  • Halford, W.P., Filed Dec 2014, “A rapid and sensitive serological assay to determine if patients are infected with HSV-1 and/or HSV-2.” A test that measures the amount of HSV-1- and/or HSV-2-specific antibodies in a patient’s blood (Read Patent)

 

Reviews and commentaries:

  • Halford, W.P. 2007. Towards an effective genital herpes vaccine: past lessons and future prospects. Future Virology 2: 1-6. (Read Article)
  • Halford, W.P. and B.M. Gebhardt. 2011. Host interferon: a silent partner in the regulation of herpes simplex virus latency. In Viruses and Interferon: Current Research, Mossman, K.L. ed., Horizon Scientific Press, Hethersett, United Kingdom.   (Read Article)
  • Halford, W.P. 2014. Antigenic breadth: a missing ingredient in HSV-2 subunit vaccines? Expert Rev Vaccines 13: 691–710. (Read Article)

 

Original Research Articles:

  • Halford, W.P. and P.A. Schaffer. 2001. ICP0 is required for the efficient reactivation of herpes simplex virus type 1 from neuronal latency. J. Virol. 75: 3240-3249. (Read Article)
  • Härle, P., B. Sainz, D.J.J. Carr, and W.P. Halford. 2002. The immediate-early protein, ICP0, is essential for the resistance of herpes simplex virus to interferon-alpha/beta. Virology. 293: 295-304. (Read Article)
  • Halford, W.P., J. Grace, C. Weisend, M. Soboleski, D.J.J. Carr, J.W. Balliet, Y. Imai, T.P. Margolis, and B.M. Gebhardt. 2006. ICP0 antagonizes Stat 1-dependent repression of herpes simplex virus: implications for the regulation of viral latency. Virol. J. 3: 44. (Read Article)
  • Halford, W.P., R. Püschel, and B. Rakowski. 2010. Herpes simplex virus 2 ICP0mutants are avirulent and immunogenic: implications for a genital herpes vaccine. PLoS ONE 5: e12251. (Read Article)
  • Halford W.P., Püschel R., Gershburg E., Wilber A., Gershburg S., Rakowski B. 2011. A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. PLoS ONE 6:e17748. (Read Article)
  • Halford, W.P., J. Geltz, and E. Gershburg. 2013. Pan-HSV-2 IgG antibody in vaccinated mice and guinea pigs correlates with protection against herpes simplex virus 2. PLoS ONE. 8:e65523. (Read Article)
  • Geltz, J., E. Gershburg, and Halford, W.P. 2015. HSV-2 infected cell proteins are among the most dominant antigens of a live-attenuated HSV-2 vaccine. PLoS ONE 10(1): e116091. (Read Article)
  • Halford, W.P., J. Geltz, R.J. Messer, and K.J. Hasenkrug. 2015. Antibodies are required for complete vaccine-induced protection against HSV-2. PLoS ONE 10(12): e145228. (Read Article)
  • Royer, D.J., R. Hem. I. Gurung, J.K. Jinkins, J.J. Geltz, J.L. Wu, W.P. Halford and D.J.J. Carr. 2016. Highly Efficacious HSV-1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology Via Humoral Immunity. J. Virol. 90(11):5514-29 (Read Article)

 

Presentations at Scientific Meetings:

  • Sowa, G, J. Geltz, A. Kempa, R. Bernert, T. Warren and Halford, W.P. 2016. ABVIC: an improved serological test to resolve indeterminate diagnoses for HSV-2, Immunology 2016, May 13-17, Seattle, WA. (Learn More)

© Rational Vaccines, Inc. Privacy Policy | Terms and Conditions